EP2151239B1 - Hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof - Google Patents
Hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof Download PDFInfo
- Publication number
- EP2151239B1 EP2151239B1 EP07710861A EP07710861A EP2151239B1 EP 2151239 B1 EP2151239 B1 EP 2151239B1 EP 07710861 A EP07710861 A EP 07710861A EP 07710861 A EP07710861 A EP 07710861A EP 2151239 B1 EP2151239 B1 EP 2151239B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- temperature
- injection
- hours
- piperphentonamine hydrochloride
- piperphentonamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 46
- 239000007924 injection Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000000843 powder Substances 0.000 title description 20
- JEJGJJSMKOHPTP-XBXARRHUSA-N (E)-5-[2-(1,3-benzodioxol-5-yl)ethyl-methylamino]-1-(4-hydroxyphenyl)pent-1-en-3-one Chemical compound C=1C=C2OCOC2=CC=1CCN(C)CCC(=O)\C=C\C1=CC=C(O)C=C1 JEJGJJSMKOHPTP-XBXARRHUSA-N 0.000 title description 4
- MXVIFUCWSSCOCK-ZFXMFRGYSA-N (E)-5-[2-(1,3-benzodioxol-5-yl)ethyl-methylamino]-1-(4-hydroxyphenyl)pent-1-en-3-one hydrochloride Chemical compound Cl.C=1C=C2OCOC2=CC=1CCN(C)CCC(=O)\C=C\C1=CC=C(O)C=C1 MXVIFUCWSSCOCK-ZFXMFRGYSA-N 0.000 claims abstract description 91
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000008215 water for injection Substances 0.000 claims abstract description 44
- 238000004108 freeze drying Methods 0.000 claims abstract description 43
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 41
- 238000007710 freezing Methods 0.000 claims abstract description 40
- 230000008014 freezing Effects 0.000 claims abstract description 40
- 238000001035 drying Methods 0.000 claims abstract description 34
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 32
- 206010019280 Heart failures Diseases 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 13
- 229930195725 Mannitol Natural products 0.000 claims abstract description 13
- 239000000594 mannitol Substances 0.000 claims abstract description 13
- 235000010355 mannitol Nutrition 0.000 claims abstract description 13
- 230000005961 cardioprotection Effects 0.000 claims abstract description 5
- 238000012856 packing Methods 0.000 claims abstract description 5
- 239000011521 glass Substances 0.000 claims abstract 2
- 230000001965 increasing effect Effects 0.000 claims description 79
- 230000003247 decreasing effect Effects 0.000 claims description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 34
- 238000005303 weighing Methods 0.000 claims description 31
- 238000001914 filtration Methods 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 11
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims 1
- 239000003929 acidic solution Substances 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 8
- 239000002932 luster Substances 0.000 abstract description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 7
- 239000008101 lactose Substances 0.000 abstract description 7
- 229930006000 Sucrose Natural products 0.000 abstract description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 6
- 235000013681 dietary sucrose Nutrition 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 6
- 229960004793 sucrose Drugs 0.000 abstract description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract description 5
- 229960000502 poloxamer Drugs 0.000 abstract description 5
- 229920001983 poloxamer Polymers 0.000 abstract description 5
- 239000004471 Glycine Substances 0.000 abstract description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 abstract description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract description 2
- 229920002307 Dextran Polymers 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 39
- 230000000694 effects Effects 0.000 description 36
- 239000000047 product Substances 0.000 description 30
- 229920001971 elastomer Polymers 0.000 description 27
- 239000000463 material Substances 0.000 description 27
- 229910001220 stainless steel Inorganic materials 0.000 description 27
- 239000010935 stainless steel Substances 0.000 description 27
- 238000001514 detection method Methods 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
- 239000011575 calcium Substances 0.000 description 16
- 229910052791 calcium Inorganic materials 0.000 description 16
- 230000002107 myocardial effect Effects 0.000 description 15
- 241000282326 Felis catus Species 0.000 description 13
- 230000000747 cardiac effect Effects 0.000 description 13
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 210000004165 myocardium Anatomy 0.000 description 9
- 229960001722 verapamil Drugs 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000004217 heart function Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000004257 Potassium Channel Human genes 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 230000003177 cardiotonic effect Effects 0.000 description 6
- NYQCKFLLTCINSJ-UHFFFAOYSA-N hydron;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;chloride Chemical compound Cl.N1C(=O)CCC(C=2C=CC(NC=3C=CN=CC=3)=CC=2)=N1 NYQCKFLLTCINSJ-UHFFFAOYSA-N 0.000 description 6
- 229960003574 milrinone Drugs 0.000 description 6
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 6
- 108020001213 potassium channel Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 102000004420 Creatine Kinase Human genes 0.000 description 5
- 108010042126 Creatine kinase Proteins 0.000 description 5
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 208000037891 myocardial injury Diseases 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- 102000013394 Troponin I Human genes 0.000 description 4
- 108010065729 Troponin I Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
- 229940122434 Calcium sensitizer Drugs 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 230000001964 calcium overload Effects 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 2
- 229960000692 levosimendan Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FHUOTRMCFQTSOA-UHFFFAOYSA-M potassium;acetic acid;acetate Chemical compound [K+].CC(O)=O.CC([O-])=O FHUOTRMCFQTSOA-UHFFFAOYSA-M 0.000 description 2
- BUCIWTBCUUHRHZ-UHFFFAOYSA-K potassium;disodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O BUCIWTBCUUHRHZ-UHFFFAOYSA-K 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- RYKKQQUKJJGFMN-HVDRVSQOSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1.CC1=NC=C(CO)C(CO)=C1O RYKKQQUKJJGFMN-HVDRVSQOSA-N 0.000 description 1
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YRBBTNSJJXHMPP-UHFFFAOYSA-N Melosatin A Chemical compound C=12C(=O)C(=O)NC2=C(OC)C(OC)=CC=1CCCCCC1=CC=CC=C1 YRBBTNSJJXHMPP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229940122117 Potassium channel agonist Drugs 0.000 description 1
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- -1 piperphentonamine compound Chemical class 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- XMFCOYRWYYXZMY-UHFFFAOYSA-N sulmazole Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=NC=CC=C2N1 XMFCOYRWYYXZMY-UHFFFAOYSA-N 0.000 description 1
- 229950006153 sulmazole Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- This invention relates to a piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof. It also relates to a use of the piperphentonamine hydrochloride lyophilized powder for injection for heart failure treatment and cardioprotection for mammals, including human.
- the "treatment” herein means both prophylactic and therapeutic.
- the piperphentonamine hydrochloride lyophilized powder for injection is also known as a piperphentonamine hydrochloride for injection.
- Heart failure is the end-stage of cardiovascular diseases and has high death rate.
- Myocardial infarction and myocardial reperfusion injury are the major factors for heart failure.
- calcium antagonists and free radical scavengers have effects on both treatment of myocardial infarction and protection against reperfusion injury, most calcium antagonists have limited clinical use as a result of inhibiting myocardial contraction and reducing heart function, and free radical scavengers do not have direct effect on heart function, which makes their clinical effect not fully established yet.
- Cardiotonics increase cardiac output by enhancing myocardial contractility to maintain the blood supply for the vital organs such as heart, brain and kidney etc.
- Vasodilators and diuretics decrease the load of the heart to protect heart function.
- the various cardiotonics such as cardiac glycosides, catecholamine, phosphodiesterase inhibitors (PDEI) and the like have high toxic side-effects, because they enhance the myocardial contractility mainly by increasing the concentration of intracellular calcium so as to cause proarrhythmic risk and prone to intracellular calcium overload.
- diuretics are used to be the first choice for treatment of cardiac failure, they can cause side effects such as electrolyte disturbance.
- ACEI angiotensin converting enzyme inhibitors
- Piperphentonamine hydrochloride is a novel cardiovascular chemical.
- the pharmacodynamic studies of PPTA demonstrated that it has good dual effects for protecting injured cardiac muscles and enhancing cardiac function with reduced myocardial oxygen consumption.
- PPTA increases the sensitivity of myocardial contractile proteins to Ca 2+ without increasing the calcium concentration inside the myocardial cells, even antagonizing intracellular calcium overload, thus suggests that it will not have the risk for proarrhythmia.
- PPTA is quickly metabolized so that it will not accumulate in the body. Concluded from the above, PPTA is calcium sensitizing cardiotonic and a myocardial protector. There has been no similar drug in the world so far.
- both the above patents have not described a composition and a preparation method of the piperphentonamine hydrochloride lyophilized powder for injection in detail, nor the use thereof.
- CN 1 476 834 A discloses metadoxin lyophilized powder for injection and preparation method thereof.
- a multistage freeze-drying method for drug solution during lyophilizing process is employed, which comprises keeping the lowest temperature at -30 to -70°C for 2 to 10 hours and rising the temperature ramped up to the highest point 0 to 70°C, keeping it for 1 to 15 hours.
- the temperature difference between the lowest and the highest point for freeze-drying is large and hard to control, and also makes a strict requirement for freeze-drying equipments.
- the object of the invention is to provide a piperphentonamine hydrochloride lyophilized powder for injection with good solubility, good stability and long storage period
- the invention provides the use of the piperphentonamine hydrochloride lyophilized powder for injection according to claim 1 for preparing a medication for treatment of heart failure as well as for cardioprotection.
- It can act as a novel cardiotonic drug with well-defined effect, low toxicity and capability of both protecting against ischemic myocardium and improving cardiac function, so as to be used for heart failure treatment and myocardial protection in both cardiac internal medicine and cardiac surgery.
- the freeze-dried powder for injection has good appearance after being freeze-dried, and the reconstituted drug solution has properties of acceptable solubility, clarity and color, namely, the piperphentonamine hydrochloride lyophilized powder is good stability and long storage period.
- piperphentonamine hydrochloride is insoluble or poor soluble in water
- the researcher of the invention finds that the piperphentonamine hydrochloride lyophilized powder for injection obtained by using conventional components and preparation method for lyophilized powder for injection will not be well shaped and will have poor solubility and stability in water for injection, it appears to be turbidity or degradation after reconstituting with water for injection, and some powder difficultly dissolved attach on the wall of the bottle.
- the lyophilized powder for injection prepared via freeze-drying has good appearance, good solubility and good storage stability.
- Piperphentonamine hydrochloride with the molecular formula C21H23NO4 ⁇ HCl has a molecular weight of 89.87, batch No. 2001803, provided by Guangzhou Zhongwei Biotechnology Ltd Company. Its preparation method is described in Chinese patent No. 02125318.8 .
- Piperphentonamine hydrochloride is difficult to be dissolved in water for injection and not stable as well, and it is easy to degrade and turn yellow. After numerous experiments, the inventors find that piperphentonamine hydrochloride treated by sonication and heating becomes easy to be dissolved in water for injection with pH 1.5 to 5.5, especially has the best solubility and stability in water for injection with pH 2 to 3.
- piperphentonamine hydrochloride and excipient need to be dissolved in water for injection with pH 1.5 to 5.5 and then lyophilized, especially preferred water for injection with pH 2 to 3.
- excipients can be used in lyophilized powder for injection, but the excipient used in the lyophilized powder for injection by intravenous administration should not affect the chemical properties of the raw materials, nor the quality detections for the powder injection. It is also required to have good solubility, capability of stuffing, and protect the active drug under the condition of low temperature and high vacuum during lyophilization.
- the results show that one of mannitol, lactose, saccharose, dextran, PEG, Poloxamer and glycine in an amount in a range from 2.5 to 30 times of the weight of piperphentonamine hydrochloride is proper for the invention.
- Mannitol accords with the related standards of Chinese Pharmacopoeia, 2000.
- the weight of Mannitol is between 2.5 and 30 times of the weight of piperphentonamine hydrochloride, especially between 5 and 20 times, more preferably from 10 to 20 times, and most preferably 10 times
- the piperphentonamine hydrochloride lyophilized powder for injection prepared by the method described above has good performance on appearance, solubility, clarity and color.
- sample appearances will be largely differed by different freeze-drying processes used in the preparation of piperphentonamine hydrochloride lyophilized powder for injection. But the freeze-drying process of the invention eliminates the differences among the freeze-dried samples. The obtained product is well shaped and has desirable freeze-drying effect.
- the present invention also provides another preparation method for piperphentonamine hydrochloride lyophilized powder for injection.
- the inventors performed freeze-dying process under the different conditions, resulting in that the obtained lyophilized powder for injection has poor appearance stability. In order to achieve good stability and save energy as well, the inventors had made many efforts to select freeze-drying processes described above.
- the lyophilized powder for injection obtained by the above methods will not have significant influence on the detection of piperphentonamine hydrochloride, and not interfere with the content measurement by HPLC. All of the appearance, solubility and clarity of the lyophilized powder are acceptable.
- the product of piperphentonamine hydrochloride lyophilized powder for injection obtained by the preparation method of the invention has the properties of content uniformity, weight variation and moisture content meeting with the quality standards for piperphentonamine hydrochloride for injection.
- the piperphentonamine hydrochloride freeze-dried powder obtained by the above method is placed into a brown bottle, said freeze-dried powder is not prone to degrade, the storage period of which is two years under light-proof condition at room temperature.
- the formulation is a calcium sensitizer for myocardial cells and a potassium channel agonist for vascular smooth muscle cells, which has treatment effects on heart failure and myocardial injury.
- Example 1 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of mannitol as excipient, placing them into a flask and adding 400ml of water for injection with pH 1.5 adjusted by 1N hydrochloric acid solution for homogenizing. Raising the temperature up to 40°C and ultrasonic dissolving till the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covered by a special rubber plug for lyophilization.
- Example 2 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of mannitol as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 50°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 3 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution to 600ml, homogenizing. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 4 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution to 600ml, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 5 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 3.5 adjusted by acetic acid-ammonium acetate buffer to 500ml, homogenizing. Raising the temperature up to 65°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering a special rubber plug for lyophilization.
- Example 6 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of mannitol as excipient, adding water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution to 500ml. Raising the temperature up to 70°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -20°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours.
- the properties of the resulted product are as follows: Detection Items Appearance Color and luster Solubility Clarity Moisture content(%) Whole loosed cake White Dissolved in 30 seconds 0.5 2.4
- Example 7 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 2.5g of saccharose as excipient, placing them into a flask and adding 400ml of water for injection with pH 4.0 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 70°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring with active carbon and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 8 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 30g of saccharose as excipient, placing them into a flask and adding 600 ml of water for injection with pH 4.5 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 80°C and ultrasonic dissolving until the materials fully dissolved, decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 9 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 20g of saccharose as excipient, placing them into a flask and adding 500 ml of water for injection with pH 5.0 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 85°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 10 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 10 g of saccharose as excipient, placing them into a flask and adding 400 ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - sodium dihydrogen phosphate buffer, homogenizing. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 11 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of dextran-20 as excipient, placing them into a flask and adding 400ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example12 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10g of dextran-20 as excipient, placing them into a flask and adding 500ml of water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 13 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20g of dextran-40 as excipient, placing them into a flask and adding 600ml of water for injection with pH 3.0 adjusted by hydrochloric acid, homogenizing. Raising the temperature up to 65°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 14 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of lactose as excipient, adding 400ml of water for injection with pH 2.0 adjusted by hydrochloric acid solution. Raising the temperature up to 45°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -35°C, then placing the samples into it for pre-freezing for 3 hours, then increasing the temperature to -20°C for freeze dehydrating for 25 hours, again increasing the temperature to 30°C for drying for 5 hours.
- the properties of the resulted product are as follows: Detection Items Appearance Color and luster Solubility Clarity Moisture content (%) Whole loose cake White Easy to dissolve in 30 seconds 0.5 2.6
- Example 15 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of lactose as excipient, adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -25°C, then placing the samples into it for pre-freezing for 7 hours, then increasing the temperature to -10°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 15 hours.
- the properties of the resulted product are as follows: Detection Items Appearance Color and luster clarity Solubility Moisture content (%) Whole loose cake White 0.5 Easy to dissolve in 30 seconds 2.4
- Example 16 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20.0g of lactose as excipient, adding water for injection with pH 3.0 adjusted by hydrochloric acid solution to 500ml. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C, then placing the samples into it for pre-freezing for 5 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours.
- the properties of the resulted product are as follows: Detection Items Appearance Color and luster Clarity Solubility Moisture content (%) Whole loose cake white 0.5 Easy to dissolve in 30 seconds 2.4
- Example 17 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25g of lactose as excipient, adding 600ml of water for injection with pH 4.5 adjusted by disodium hydrogen phosphate - potassium dihydrogen phosphate buffer. Raising the temperature up to 75°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 18 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of lactose as excipient, adding 500ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - potassium dihydrogen phosphate buffer. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 19 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of PEG1500 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 50°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 20 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of PEG4000 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- the properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 21 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of PEG6000 as excipient, placing them into a flask and adding 600ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - sodium dihydrogen phosphate buffer. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- the properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 22 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20g of PEG4000 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 23 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of Poloxamer as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by o-phthalic acid-hydrochloric acid buffer. Raising the temperature up to 40°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization.
- Example 24 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25.0g of Poloxamer as excipient, placing them into a flask and adding 400ml of water for injection with pH 3.5 adjusted by acetic acid-ammonium acetate buffer. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization.
- the properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 25 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of Poloxamer as excipient, placing them into a flask and adding 600ml of water for injection with pH 5.0 adjusted by acetic acid-potassium acetate buffer. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization.
- the properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 26 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10g of glycine as excipient, placing them into a flask and adding 500ml of water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization.
- the properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 27 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of glycine as excipient, placing them into a flask and adding water for injection with pH 5.5 adjusted by acetic acid-potassium acetate buffer to 600ml. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization.
- Example 28 comprises the steps of: packing the piperphentonamine hydrochloride freeze-dried powders for injection prepared by any one of preraration methods in the above described Example 1 to 27 into the brown bottles with the special bottle plugs made of butyl rubber for lyophilization. Under the conditions of high temperature (40°C) and strong light (4200Lx), taking samples for test on the 5th and 10th day respectively.
- Example 29 comprises the steps of: packing the piperphentonamine hydrochloride freeze-dried powders for injection prepared by any one of the preparation methods in the above described Example 1 to 27 into brown bottles with the special bottle plugs made of butyl rubber for lyophilization. Observing the stability by the accelerated test, testing the appearances, the clarities of the solution, pH, moisture contents, related substances and contents after the products being placed at temperature of 40°C and related humidity of 75% for 0, 1, 2, 3, and 6 months.
- This example relates to the calcium sensitization experiments of the piperphentonamine hydrochloride lyophilized powder for injection (Piperphentonamine hydrochloride for injection, PPTA-I)
- the cTnC-Ca 2+ affinity curve is shifted to the left by characteristic of dose-dependent of piperphentonamine hydrochloride: slightly shifted to the left without statistical significance at 15 ⁇ mol/L; shifted to the left with statistical significance at 35 ⁇ mol/L; and shifted more significantly at 55 ⁇ mol/L by 0.2 pCa to the left compared with the control curve ( Fig. 3 ). 55 ⁇ mol/L of MCI-154 or Sul showed no significant effect on the cTnC- Ca 2+ affinity curve ( Fig. 4 ).
- PPTA-I increasing the affinity of cTn C to Ca 2+ dose-dependently explains the calcium sensitivity of the PPTA-I on molecular level, implying that this effect may be one pathway that PPTA-I increasing myocardial calcium sensitivity and thereby promoting the myocardial contractility.
- This example relates to the experiment for the effect of PPTA-I on potassium channel of vascular smooth muscle.
- This example relates to the experiment for the therapeutic effect of the piperphentonamine hydrochloride for injection (PPTA-I) on heart failure.
- the cardiac hemodynamic parameters were determined by a polygraph in cat heart failure model induced by verapamil.
- the results showed that 4 or 8 mg/kg of PPTA-I administered intravenously slightly decreased heart rate(HR) and blood pressure(BP), it also decreased the decline rate of left ventricular pressure (-dP/dt max),but not changing the left ventricular systolic pressure (LVSP), end-diastolic pressure(LVEDP) and rise rate of left ventricular pressure (+dP/dt max).
- the myocardial contractility was also improved by the PPTA-I in animals with heart failure, a similar effect to that of Milrinone.
- PPTA-I 4 mg/kg administered increased LVSP by 10 ⁇ 9 % (P ⁇ 0.01) and decreased +dP/dt max by 22 ⁇ 32 %(P ⁇ 0.05) compared with baselines, but without significant difference compared to solvent control.
- -dP/dt max was decreased by 35 ⁇ 12 % at most after administration and lasted for 20 minutes, with significant difference compared to the solvent control.
- PPTA-I 8 mg/kg did not affect the LVSP, LVEDP and ⁇ dP/dt max in cat cardiac failure model induced by verapamil.
- PPTA-I slightly decreases the HR and BP in cat heart failure model induced by verapamil, and significantly increase the myocardial contractility and +dP/dt max, indicating that PPTA-I has the effect for improving cardiac function.
- This example relates to the experiment for cardioprotection effect of the piperphentonamine hydrochloride for injection (PPTA-I).
- the serum biochemistry results showed that PPTA-I 1.2 to 4.8 mg/kg could antagonize dose-dependently the increase of the final product of lipid-peroxidation malonaldehyde (MDA) produced by ischemia-reperfusion, decrease the activity of creatine phosphokinase (CPK) and the amount of Troponin-I (TnI).
- MDA lipid-peroxidation malonaldehyde
- CPK creatine phosphokinase
- TnI Troponin-I
- This example relates to the clinical use of piperphentonamine hydrochloride for injection (PPTA-I) for treatment of heart failure and protection of injured myocardium.
- the dose for heart failure is 0.5mg/kg, administered by intravenous bolus of 10% of the dose plus intravenous infusion of remained 90% of the dose.
- the treatment course is 7 days.
- the results are shown in Table 6.
- the dose for myocardial protection is 1.0mg/kg, administered by intravenous infusion or adding into the cardioplegia liquid used in cardiosurgical operation for cardiac perfusion.
- the treatment course is 7 days as well.
- Table 6 The clinical efficacies of PPTA-I on acute and chronic cardiac dysfunction.
Abstract
Description
- This invention relates to a piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof. It also relates to a use of the piperphentonamine hydrochloride lyophilized powder for injection for heart failure treatment and cardioprotection for mammals, including human. The "treatment" herein means both prophylactic and therapeutic. The piperphentonamine hydrochloride lyophilized powder for injection is also known as a piperphentonamine hydrochloride for injection.
- Heart failure is the end-stage of cardiovascular diseases and has high death rate. Myocardial infarction and myocardial reperfusion injury are the major factors for heart failure. Although the experimental studies both in china and abroad have been revealed that calcium antagonists and free radical scavengers have effects on both treatment of myocardial infarction and protection against reperfusion injury, most calcium antagonists have limited clinical use as a result of inhibiting myocardial contraction and reducing heart function, and free radical scavengers do not have direct effect on heart function, which makes their clinical effect not fully established yet.
- The therapeutic principles for heart failure are increasing heart function, vasodilating and diuretic therapy. Cardiotonics increase cardiac output by enhancing myocardial contractility to maintain the blood supply for the vital organs such as heart, brain and kidney etc.. Vasodilators and diuretics decrease the load of the heart to protect heart function. However, the various cardiotonics such as cardiac glycosides, catecholamine, phosphodiesterase inhibitors (PDEI) and the like have high toxic side-effects, because they enhance the myocardial contractility mainly by increasing the concentration of intracellular calcium so as to cause proarrhythmic risk and prone to intracellular calcium overload. Although diuretics are used to be the first choice for treatment of cardiac failure, they can cause side effects such as electrolyte disturbance. Recent studies have demonstrated that angiotensin converting enzyme inhibitors (ACEI) have the effects of treating congestive heart failure and protecting cardiac muscles against ischemia and reperfusion injury, but their long term effectiveness needs to be observed.
- Piperphentonamine hydrochloride (PPTA) is a novel cardiovascular chemical. The pharmacodynamic studies of PPTA demonstrated that it has good dual effects for protecting injured cardiac muscles and enhancing cardiac function with reduced myocardial oxygen consumption. PPTA increases the sensitivity of myocardial contractile proteins to Ca2+ without increasing the calcium concentration inside the myocardial cells, even antagonizing intracellular calcium overload, thus suggests that it will not have the risk for proarrhythmia. PPTA is quickly metabolized so that it will not accumulate in the body. Concluded from the above, PPTA is calcium sensitizing cardiotonic and a myocardial protector. There has been no similar drug in the world so far. The chemical structure of Levosimendan (Simdax), the first calcium sensitizing cardiotonic in the world, marketed by Orion Corporation, Finland in 2000, has totally different from PPTA's. The systemic toxicity studies showed that PPTA is low toxic and has high therapeutic index. The raw materials required to synthesize PPTA are readily available and stable for storage under normal temperature. The synthesizing process is simple and environment friendly, and the production cost is low. The dosage form of PPTA is lyophilized powder for injection.
-
CN 1396162 A entitled "Piperphentonamine, its salts and preparation method thereof, discloses a piperphentonamine compound, its salts and preparation method thereof, and mentions that the synthetic piperphentonamine hydrochloride has high purity and little toxic side-effect, it is promising to be developed into a novel drug for treatment of heart failure and protection against ischemia and reperfusion injury. -
CN 1 395 923 A entitled "The use of piperphentonamine and salts thereof in the preparation of a medication for treatment cardiovascular diseases", disclosed that piperphentonamine or its pharmaceutical acceptable salts can be formulated into solution, powder, tablet or capsule for intravenous injection, muscle injection and oral administration respectively, with a dosage from 0.1 to 1.0mg/kg. But both the above patents have not described a composition and a preparation method of the piperphentonamine hydrochloride lyophilized powder for injection in detail, nor the use thereof. -
CN 1 476 834 A discloses metadoxin lyophilized powder for injection and preparation method thereof. A multistage freeze-drying method for drug solution during lyophilizing process is employed, which comprises keeping the lowest temperature at -30 to -70°C for 2 to 10 hours and rising the temperature ramped up to the highest point 0 to 70°C, keeping it for 1 to 15 hours. The temperature difference between the lowest and the highest point for freeze-drying is large and hard to control, and also makes a strict requirement for freeze-drying equipments. - The object of the invention is to provide a piperphentonamine hydrochloride lyophilized powder for injection with good solubility, good stability and long storage period
- This technical problem is solved by a powder as defined in claims 1 and 2, as well as by a method as defined in claims 3 and 4.
- Further, the invention provides the use of the piperphentonamine hydrochloride lyophilized powder for injection according to claim 1 for preparing a medication for treatment of heart failure as well as for cardioprotection.
- It can act as a novel cardiotonic drug with well-defined effect, low toxicity and capability of both protecting against ischemic myocardium and improving cardiac function, so as to be used for heart failure treatment and myocardial protection in both cardiac internal medicine and cardiac surgery.
- The freeze-dried powder for injection has good appearance after being freeze-dried, and the reconstituted drug solution has properties of acceptable solubility, clarity and color, namely, the piperphentonamine hydrochloride lyophilized powder is good stability and long storage period.
- It is conventionally known that piperphentonamine hydrochloride is insoluble or poor soluble in water, the researcher of the invention finds that the piperphentonamine hydrochloride lyophilized powder for injection obtained by using conventional components and preparation method for lyophilized powder for injection will not be well shaped and will have poor solubility and stability in water for injection, it appears to be turbidity or degradation after reconstituting with water for injection, and some powder difficultly dissolved attach on the wall of the bottle. But when piperphentonamine hydrochloride and the excipient of the invention are dissolved in the water for injection with pH 1.5 to 5.5 and packaged into a brown bottle, the lyophilized powder for injection prepared via freeze-drying has good appearance, good solubility and good storage stability.
- Piperphentonamine hydrochloride with the molecular formula C21H23NO4·HCl has a molecular weight of 89.87, batch No. 2001803, provided by Guangzhou Zhongwei Biotechnology Ltd Company. Its preparation method is described in Chinese patent No.
02125318.8 . Piperphentonamine hydrochloride is difficult to be dissolved in water for injection and not stable as well, and it is easy to degrade and turn yellow. After numerous experiments, the inventors find that piperphentonamine hydrochloride treated by sonication and heating becomes easy to be dissolved in water for injection with pH 1.5 to 5.5, especially has the best solubility and stability in water for injection with pH 2 to 3. In order to achieve the lyophilized powder for injection with good redissolving ability and stability, piperphentonamine hydrochloride and excipient need to be dissolved in water for injection with pH 1.5 to 5.5 and then lyophilized, especially preferred water for injection with pH 2 to 3. - Many kinds of excipients can be used in lyophilized powder for injection, but the excipient used in the lyophilized powder for injection by intravenous administration should not affect the chemical properties of the raw materials, nor the quality detections for the powder injection. It is also required to have good solubility, capability of stuffing, and protect the active drug under the condition of low temperature and high vacuum during lyophilization. The results show that one of mannitol, lactose, saccharose, dextran, PEG, Poloxamer and glycine in an amount in a range from 2.5 to 30 times of the weight of piperphentonamine hydrochloride is proper for the invention.
- Mannitol accords with the related standards of Chinese Pharmacopoeia, 2000. When the weight of Mannitol is between 2.5 and 30 times of the weight of piperphentonamine hydrochloride, especially between 5 and 20 times, more preferably from 10 to 20 times, and most preferably 10 times, the piperphentonamine hydrochloride lyophilized powder for injection prepared by the method described above has good performance on appearance, solubility, clarity and color.
- The sample appearances will be largely differed by different freeze-drying processes used in the preparation of piperphentonamine hydrochloride lyophilized powder for injection. But the freeze-drying process of the invention eliminates the differences among the freeze-dried samples. The obtained product is well shaped and has desirable freeze-drying effect.
- The present invention also provides another preparation method for piperphentonamine hydrochloride lyophilized powder for injection. The inventors performed freeze-dying process under the different conditions, resulting in that the obtained lyophilized powder for injection has poor appearance stability. In order to achieve good stability and save energy as well, the inventors had made many efforts to select freeze-drying processes described above.
- The appearance, solubility and clarity of the samples hasn't significant difference by either the pre-freezing method with fast freezing showed in
Fig. 1 or the pre-freezing method with slow freezing showed inFig. 2 . The temperature range between the lowest and highest point is suitable for freeze-drying compared with that the one described in the above Chinese patent No.03141625.X , which is easy to control and will not lead to a strict requirement for the equipments. The energy consumption is less than that in the reference. - The lyophilized powder for injection obtained by the above methods will not have significant influence on the detection of piperphentonamine hydrochloride, and not interfere with the content measurement by HPLC. All of the appearance, solubility and clarity of the lyophilized powder are acceptable.
- After numerous repeated experiments, the product of piperphentonamine hydrochloride lyophilized powder for injection obtained by the preparation method of the invention has the properties of content uniformity, weight variation and moisture content meeting with the quality standards for piperphentonamine hydrochloride for injection.
- The piperphentonamine hydrochloride freeze-dried powder obtained by the above method is placed into a brown bottle, said freeze-dried powder is not prone to degrade, the storage period of which is two years under light-proof condition at room temperature.
- The pharmacology studies performed for the lyophilized powder for injection demonstrated that: the formulation is a calcium sensitizer for myocardial cells and a potassium channel agonist for vascular smooth muscle cells, which has treatment effects on heart failure and myocardial injury.
-
-
Fig. 1 The freeze-drying curve of piperphentonamine hydrochloride for pre-freezing method with fast freezing. -
Fig. 2 The freeze-drying curve of piperphentonamine hydrochloride for pre-freezing method with slow freezing. -
Fig. 3 The effects of the different concentrations of piperphentonamine hydrochloride on the fluorescence affinity curve of cTn C to Ca2+ . -
Fig. 4 The effect of 50 µmol/L of MCI-154 and Sul on the fluorescence affinity curve of cTn C to Ca2+. -
Fig. 5 The effect of 0.1 µmol/L of PPTA-I on the current-voltage curve of whole cell Ca2+-sensitive-potassium channel. -
Fig. 6 The effect of 0.01-10 µmol/L of PPTA-I on the current-voltage curve of whole cell Ca2+-sensitive-potassium channel. - The following examples 1 to 6 are used to illustrate the invention. Examples 7 to 27 are disclosed for the purpose of information only and do not form part of the invention.
- Example 1 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of mannitol as excipient, placing them into a flask and adding 400ml of water for injection with pH 1.5 adjusted by 1N hydrochloric acid solution for homogenizing. Raising the temperature up to 40°C and ultrasonic dissolving till the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covered by a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -25°C, placing the samples into it for pre-freezing for 3 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility Shaped, loosened by fillip with slightly forcing, without shrinkage 2.0 YG1-2 0.5 Easy to dissolve in water - Example 2 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of mannitol as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 50°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C, placing the samples into it for pre-freezing for 5 hours, then increasing the temperature to -20°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility White, whole loose cake 2.5 YG1-2 0.5 Easy to dissolve in water - Example 3 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution to 600ml, homogenizing. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -30°C for pre-freezing for 4 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows: shaped, good appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear, and colorYG1-2.
- Example 4 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution to 600ml, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, good appearance, not changing shape by a fillip with slightly forcing fillip, easy to dissolve, clear, and colorYG1-2.
- Example 5 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25 g of mannitol as excipient, placing them into a flask and adding water for injection with pH 3.5 adjusted by acetic acid-ammonium acetate buffer to 500ml, homogenizing. Raising the temperature up to 65°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -35°C for pre-freezing for 2 hours, then increasing the temperature to -10°C for freeze dehydrating for 25 hours, again increasing the temperature to 30°C for drying for 15 hours. The properties of the resulted product are as follows: shaped, good appearance, not changing shape by a slightly forced fillip, easy to dissolve, clear, and color YG1-2.
- Example 6 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of mannitol as excipient, adding water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution to 500ml. Raising the temperature up to 70°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -20°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Solubility Clarity Moisture content(%) Whole loosed cake White Dissolved in 30 seconds 0.5 2.4 - Example 7 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 2.5g of saccharose as excipient, placing them into a flask and adding 400ml of water for injection with pH 4.0 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 70°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring with active carbon and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -35°C, placing the samples into it for pre-freezing for 7 hours, then increasing the temperature to -20°C for freeze dehydrating for 25 hours, again increasing the temperature to 30°C for drying for 15 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility Shaped, not changing shape by a fillip with slightly forcing 4.4 YG1-2 0.5 Easy to dissolve in water - Example 8 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 30g of saccharose as excipient, placing them into a flask and adding 600 ml of water for injection with pH 4.5 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 80°C and ultrasonic dissolving until the materials fully dissolved, decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -25°C, placing the samples into it for pre-freezing for 3 hours, then increasing the temperature to -10°C for freeze dehydrating for 25 hours, again increasing the temperature to 30°C for drying for 15 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility Shaped, acceptable appearance 4.5 YG1-2 0.5 Easy to dissolve in water - Example 9 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 20g of saccharose as excipient, placing them into a flask and adding 500 ml of water for injection with pH 5.0 adjusted by acetic acid-ammonium acetate buffer, homogenizing. Raising the temperature up to 85°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the samples into the sample chamber, then decreasing the temperature of the sample chamber to -30°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility Shaped, acceptable appearance 5.1 YG1-2 0.5 Easy to dissolve in water - Example 10 comprises the steps of: weighing 1.0 g of piperphentonamine hydrochloride and 10 g of saccharose as excipient, placing them into a flask and adding 400 ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - sodium dihydrogen phosphate buffer, homogenizing. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), decoloring by active carbon adsorption and leaching the active carbon, degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the samples into the sample chamber, then decreasing the temperature of the sample chamber to -35°C for pre-freezing for 4 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility Shaped, acceptable appearance 5.5 YG1-2 0.5 Easy to dissolve in water - Example 11 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of dextran-20 as excipient, placing them into a flask and adding 400ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -35°C, then placing the split charged samples into it for pre-freezing for 7 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility White, loosed cake, hardly changing shape and shrinkage 2.5 YG1-2 1.0 Easy to dissolve in water - Example12 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10g of dextran-20 as excipient, placing them into a flask and adding 500ml of water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature to -25°C for pre-freezing for 3 hours, then increasing the temperature to -10°C for drying for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility White, loosen cake, hardly changing shape and shrinkage 3.5 YG1-2 1.0 Easy to dissolve in water - Example 13 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20g of dextran-40 as excipient, placing them into a flask and adding 600ml of water for injection with pH 3.0 adjusted by hydrochloric acid, homogenizing. Raising the temperature up to 65°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the lyophilizing chamber, then decreasing the temperature to -35°C for pre-freezing for 4 hours, then increasing the temperature to -20°C for drying for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility White, loose cake, hardly changing shape and shrinkage 3.5 YG1-2 1.0 Easy to dissolve in water - Example 14 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of lactose as excipient, adding 400ml of water for injection with pH 2.0 adjusted by hydrochloric acid solution. Raising the temperature up to 45°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -35°C, then placing the samples into it for pre-freezing for 3 hours, then increasing the temperature to -20°C for freeze dehydrating for 25 hours, again increasing the temperature to 30°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Solubility Clarity Moisture content (%) Whole loose cake White Easy to dissolve in 30 seconds 0.5 2.6 - Example 15 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of lactose as excipient, adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 55°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -25°C, then placing the samples into it for pre-freezing for 7 hours, then increasing the temperature to -10°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 15 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster clarity Solubility Moisture content (%) Whole loose cake White 0.5 Easy to dissolve in 30 seconds 2.4 - Example 16 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20.0g of lactose as excipient, adding water for injection with pH 3.0 adjusted by hydrochloric acid solution to 500ml. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C, then placing the samples into it for pre-freezing for 5 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Clarity Solubility Moisture content (%) Whole loose cake white 0.5 Easy to dissolve in 30 seconds 2.4 - Example 17 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25g of lactose as excipient, adding 600ml of water for injection with pH 4.5 adjusted by disodium hydrogen phosphate - potassium dihydrogen phosphate buffer. Raising the temperature up to 75°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the samples into the sample chamber and decreasing the temperature to -25°C for pre-freezing for 2 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 20°C for drying for 5 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Clarity Solubility Moisture content (%) Whole loose cake White 0.5 Easy to dissolve in 30 seconds 2.4 - Example 18 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10.0g of lactose as excipient, adding 500ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - potassium dihydrogen phosphate buffer. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature to -25°C for pre-freezing for 4 hours, then increasing the temperature to -20°C for freeze dehydrating for 15 hours, again increasing the temperature to 30°C for drying for 15 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Clarity Solubility Moisture content (%) Whole loose cake White 0.5 Easy to dissolve in 30 seconds 2.4 - Example 19 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of PEG1500 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 50°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C, then placing the samples into it for pre-freezing for 5 hours, then increasing the temperature to -20°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance Color and luster Color Clarity Solubility pH Whole loose cake White YG1-2 0.5 Easy to dissolve in water 2.8 - Example 20 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of PEG4000 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 21 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of PEG6000 as excipient, placing them into a flask and adding 600ml of water for injection with pH 5.5 adjusted by disodium hydrogen phosphate - sodium dihydrogen phosphate buffer. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 22 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 20g of PEG4000 as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.5 adjusted by 1N hydrochloric acid solution. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a slightly forcing fillip, easy to dissolve, clear and color YG1-2.
- Example 23 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 2.5g of Poloxamer as excipient, placing them into a flask and adding 500ml of water for injection with pH 2.0 adjusted by o-phthalic acid-hydrochloric acid buffer. Raising the temperature up to 40°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, and half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C, then placing the samples into it for pre-freezing for 5 hours, then increasing the temperature to -20°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows:
Detection Items Appearance pH Color Clarity Solubility White, whole loose cake 2.5 YG1-2 0.5 Easy to dissolve in water - Example 24 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 25.0g of Poloxamer as excipient, placing them into a flask and adding 400ml of water for injection with pH 3.5 adjusted by acetic acid-ammonium acetate buffer. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 25 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of Poloxamer as excipient, placing them into a flask and adding 600ml of water for injection with pH 5.0 adjusted by acetic acid-potassium acetate buffer. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 26 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 10g of glycine as excipient, placing them into a flask and adding 500ml of water for injection with pH 3.0 adjusted by 1N hydrochloric acid solution, homogenizing. Raising the temperature up to 60°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Placing the split charged samples into the sample chamber, then decreasing the temperature of the sample chamber to -25°C for pre-freezing for 3 hours, then increasing the temperature to -15°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 27 comprises the steps of: weighing 1.0g of piperphentonamine hydrochloride and 30.0g of glycine as excipient, placing them into a flask and adding water for injection with pH 5.5 adjusted by acetic acid-potassium acetate buffer to 600ml. Raising the temperature up to 90°C and ultrasonic dissolving until the materials fully dissolved (about 10 minutes), degerming by positive pressure filtering using stainless steel filter, split charging by 5ml per vial, half covering with a special rubber plug for lyophilization. Decreasing the temperature of the sample chamber to -30°C,then placing the split charged samples into it for pre-freezing for 5 hours, then increasing the temperature to -20°C for freeze dehydrating for 20 hours, again increasing the temperature to 25°C for drying for 10 hours. The properties of the resulted product are as follows: shaped, excellent appearance, not changing shape by a fillip with slightly forcing, easy to dissolve, clear and color YG1-2.
- Example 28 comprises the steps of: packing the piperphentonamine hydrochloride freeze-dried powders for injection prepared by any one of preraration methods in the above described Example 1 to 27 into the brown bottles with the special bottle plugs made of butyl rubber for lyophilization. Under the conditions of high temperature (40°C) and strong light (4200Lx), taking samples for test on the 5th and 10th day respectively. The test results are shown below:
The results of the influencing factors for piperphentonamine hydrochloride lyophilized powder for injection Time (day) 0 5 10 Condition Normal temperature, daylight 40°C 4200Lx 40°C 4200Lx Appearance White freeze-dried powder White freeze-dried powder White freeze-dried powder White freeze-dried powder White freeze-dried powder Color of solution YG1 YG1-2 YG1-2 YG1-2 YG1-2 Clarity Acceptable Acceptable Acceptable Acceptable Acceptable pH 2.0-5.5 Not significantly changed Not significantly changed Not significantly changed Not significantly changed Moisture content 1.0%-3.0% Not significantly changed Not significantly changed Not significantly changed Not significantly changed Related substances Acceptable Acceptable Acceptable Acceptable Acceptable Nominal content 104.8% 104.0% 100.7% 103.9% 103.8% 104.3% 103.5% 102.2% 102.9% 104.8% Note: the clarity is specified as no more than that of No.3 standard turbid solution(Chinese Pharmacopoeia 2005, Part II, Appendix IX B); the individual related substance is not more than 1%, and the total related substances is not more than 2%. - Example 29 comprises the steps of: packing the piperphentonamine hydrochloride freeze-dried powders for injection prepared by any one of the preparation methods in the above described Example 1 to 27 into brown bottles with the special bottle plugs made of butyl rubber for lyophilization. Observing the stability by the accelerated test, testing the appearances, the clarities of the solution, pH, moisture contents, related substances and contents after the products being placed at temperature of 40°C and related humidity of 75% for 0, 1, 2, 3, and 6 months. The test results are shown below:
Time (month) 0 1 2 3 6 Appearance White freeze-dried powder White freeze-dried powder White freeze-dried powder White freeze-dried powder White freeze-dried powder Color of solution Comparable to YG1 Comparable to YG1 between YG1 and YG2 between YG1 and YG2 between YG1 and YG2 Clarity Acceptable Acceptable Acceptable Acceptable Acceptable pH 2.0-5.5 2.0-5.5 2.0-5.5 2.0-5.5 2.0-5.5 Moisture Content(%) 1.0-4.0 1.0-4.0 1.0-4.0 1.0-4.0 1.0-4.0 Impurity from degradation Individual<1.0%; total<2.0% Individual<1.0%; total<2.0% Individual<1.0%; total<2.0% Individual<1.0%; total<2.0% Individual<1.0%; total<2.0% Nominal content 103.8% 103.9% 104.0% 101.6% 102.7% 104.2% 102.5% 103.4% 101.7% 104.1% - This example relates to the calcium sensitization experiments of the piperphentonamine hydrochloride lyophilized powder for injection (Piperphentonamine hydrochloride for injection, PPTA-I)
- The effect of PPTA-I on the affinity of Ca2+ to cTnC isolated from cattle cardiac muscle was studied by fluorescent probe dansyl chloride labeling to discuss the calcium sensitization mechanisms of piperphentonamine hydrochloride, and compared the results to the already known calcium sensitizers MCI-154 and sulmazole(Sul). The results show that PPTA-I increase the affinity of cTnC to Ca2+ obviously and dose-dependently. By contrast, 50 µmol/L of MCI-154 and Sul showed no significant influence on the affinity curve of cTnC to Ca2+. The results indicate that the calcium sensitizing mechanism of PPTA-I may be mediated by increasing the affinity of cTnC to Ca2+ directly.
- The cTnC-Ca2+ affinity curve is shifted to the left by characteristic of dose-dependent of piperphentonamine hydrochloride: slightly shifted to the left without statistical significance at 15µmol/L; shifted to the left with statistical significance at 35µmol/L; and shifted more significantly at 55µmol/L by 0.2 pCa to the left compared with the control curve (
Fig. 3 ). 55µmol/L of MCI-154 or Sul showed no significant effect on the cTnC- Ca2+ affinity curve (Fig. 4 ). - PPTA-I increasing the affinity of cTn C to Ca2+ dose-dependently explains the calcium sensitivity of the PPTA-I on molecular level, implying that this effect may be one pathway that PPTA-I increasing myocardial calcium sensitivity and thereby promoting the myocardial contractility.
- Sul and MCI-154 are well-established calcium sensitizers, but their special calcium sensitization mechanisms have still not been totally clear. The present experiment did not demonstrate their direct action of increasing the affinity of cTn C to Ca2+, as described by the literatures, suggesting the calcium sensitization effect of Sul or MCI-154 is different from that of PPTA-I in that it achieves this effect otherwise rather than increasing the affinity of cTn C to Ca2+ directly.
- This example relates to the experiment for the effect of PPTA-I on potassium channel of vascular smooth muscle.
- For further studying the mechanism underlying the vasodilative effect of PPTA-I, the effect of PPTA-I on the current of calcium-sensitive potassium channel in smooth muscle cells of rabbit mesentery resistance vessel was investigated by whole-cell patch clamp technique. The results showed that 0.12µmol/L PPTA-I significantly increased the current of the calcium-sensitive potassium channel and the current recovered to baseline after washing; PPTA-I dose-dependently increased the current of the calcium-sensitive potassium channel in the concentration range from 0.012 to 12µmol/L.
- The perfusion was paused under whole-cell patch clamp mode, adding equal volume of solvent control at first for recording the current curve 3 minutes thereafter, and then adding 0.12 µmol/L of PPTA-I for same recording, the current curve of the latter showed a significant increase of outward current. Washed by perfusate for 3 minutes, the current curve was returned to baseline level. It demonstrated that the current-voltage relation curves are significantly different between before and after administration by t test (
Fig. 5 ). - The perfusion was paused under whole-cell patch clamp mode and voltage clamping, adding targeted concentrations of PPTA-I (1.2×10-8∼1.2×10-5 mol/L) to the cell well by cumulating concentrations, recording the current curve of each concentration. The administering interval is 3 minutes. The result showed that PPTA-I increases the current significantly and dose-dependently. (
Fig. 6 ) - Conclusions: PPTA-I increases the current of calcium sensitive potassium channel in vascular smooth muscle cells dose-dependently and reversibly.
- This example relates to the experiment for the therapeutic effect of the piperphentonamine hydrochloride for injection (PPTA-I) on heart failure.
- To study the therapeutic effect of the novel cardiotonic and vasodilator PPTA-I on heart failure, the cardiac hemodynamic parameters were determined by a polygraph in cat heart failure model induced by verapamil. The results showed that 4 or 8 mg/kg of PPTA-I administered intravenously slightly decreased heart rate(HR) and blood pressure(BP), it also decreased the decline rate of left ventricular pressure (-dP/dt max),but not changing the left ventricular systolic pressure (LVSP), end-diastolic pressure(LVEDP) and rise rate of left ventricular pressure (+dP/dt max). The myocardial contractility was also improved by the PPTA-I in animals with heart failure, a similar effect to that of Milrinone. This study indicated that the contractile function is improved in cat heart failure model induced by verapamil.
Table 1. Cardiac hemodynamic parameters in Cat heart failure model induced by verapamil. (N=12) Before heart failure After heart failure Value Value Change (%) HR, bpm 131±44 68±24 *** -46±14 *** MAP#, mmHg 115±34 69±25 ** -39±13 *** LVSP, mmHg 148±41 93±27 ** -36±9 *** LVEDP, mmHg 8±7 10±9 55±87 * +dP/dt max, mmHg/s 8250±3750 3817±1755 ** -52±11 *** -dP/dt max, mmHg/s 3750±2494 1904±815 * -34±37 ** Cardiac contractility, g 97±37 63±28 * -35±13 *** MAP: Mean arterial pressure
* P<0.05 ** P<0.01 *** P<0.00 vs. before heart failure. - PPTA-I 4 mg/kg administered intravenously slightly decreased the HRs and BPs in cats with heart failure. The HR and MAP were decreased by 16±7 % and 14±10% compared with those of before administration respectively for a time period of 10 to 15 minutes. The effects were not further increased by increasing the dose to 8 mg/kg. Two minutes after 4 mg/kg of PPTA-I administered, the cardiac contractility was increased by 30±21 % compared with baseline and increased by 57±53 % at most after 8 mg/kg administered.
- Milrinone 0.1 mg/kg did not affect HRs in cats with cardiac failure, and decreased the MAP by 10% and increased the cardiac contractility by 92±80 % compared with baseline for a period of only 5 minutes (Table 2).
Table 2. The effects of PPTA-I on HR, BP and cardiac contractility in cat cardiac failure model induced by verapamil. Time Solvent PPTA-I mg/kg Milrinone min 0.8 ml/kg 4 8 0.1 mg/kg N=6 N=9 N=9 N=9 HR Baseline ,bpm 90±24 65±25 54±21 41±20 Change % 2 -1±3 11±11 * 9±9 * 0±5 5 -3±4 -15±15 * -15±17 * 2±15 10 3±5 -16±7 ***## -17±21 * 2±16 15 -3±4 -12±7 ***# -21±18 ** 3±16 20 -4±4 -9±6 ** -22±20 ** -13±37 MAP Baseline, mmHg 67± 13 76±27 66±24 51±20 Change % 2 -1±5 -14±10 **# -16±12 **# -4±4 * 5 -1±6 -11±8 ***# -16±14 **# -10±8 **# 10 0±4 -13±9 ***## -16±17 * -10±6 ***## 15 0±7 -10±11 ** -18±13 **# -10±8 **# 20 -2±5 -2±17 -14±13 ** -8±12 Cardiac contractility Baseline, g 70±41 36±17 34±26 35±29 Change % 2 -2±5 30±21 **## 50±54 *# 38±32 **# 5 -3±3 30±36 * 57±53 **# 92±80 **# 10 4±7 4±31 50±61 * 71±78 * 15 1±13 -5±49 30±48 58±74 * 20 5±8 21±83 19±51 61±69 * * P<0.05 ** P<0.01 *** P<0.001 vs. baseline
# P<0.05 ## P<0.01 vs. solvent control - PPTA-I 4 mg/kg administered increased LVSP by 10±9 % (P<0.01) and decreased +dP/dt max by 22±32 %(P<0.05) compared with baselines, but without significant difference compared to solvent control. -dP/dt max was decreased by 35±12 % at most after administration and lasted for 20 minutes, with significant difference compared to the solvent control. PPTA-I 8 mg/kg did not affect the LVSP, LVEDP and ±dP/dt max in cat cardiac failure model induced by verapamil. Milrinone 0.1 mg/kg increased +dP/dt max by 61±26 % at most for a period over 20 minutes, but without changing LVSP, LVEDP and -dP/dt max in cats with cardiac failure (Table 3 and 4)
Table 3. The effect of PPTA-I on left ventricular pressure in cat cardiac failure model induced by verapamil Time Solvent PPTA-I mg/kg Milrinone min 0.8 ml/kg 4 8 0.1 mg/kg N=6 N=9 N=9 N=9 LVSP Baseline, mmHg 86±16 107±38 102±39 85±25 Change, % 2 5±7 6±6 ** -2±7 4±11 5 5±7 10±9 ** -1±12 5±15 10 6±8 0±14 -4±15 6±17 15 6±7 -1±14 -9±14 3±18 20 6±7 -2±27 -3±10 4±22 LVEDP Baseline, mmHg 7±6 13±9 17±9 17±9 Change, % 2 -1±12 3±13 9±18 1±2 5 -1±12 2±21 23±40 5±16 10 3±9 5±19 17±35 -1±5 15 -3±17 2±11 4±37 -7±16 20 3±9 11±8** 9±40 2±11 ** P<0.01 vs. baseline Table 4. The effect of PPTA-I on left ventricular dp/dt max in cat cardiac failure model induced by verapamil Time Solvent PPTA-I mg/kg Milrinone min 0.8 ml/kg 4 8 0.1 mg/kg N=6 N=9 N=9 N=9 +dP/dt max Baseline, mmHg/s 4467±1148 4061±1997 3372±1845 1917±1094 Change, % 2 -1±7 6±27 3±22 18±23 * 5 -1±7 5±30 1±40 52±24 ***### 10 3±6 -17±27 * -1±42 61±26 ***### 15 2±7 -22±32 * -7±49 54±33 ***## 20 2±8 -6±49 -7±40 61±45 **# -dP/dt max Baseline, mmHg/s 2417±639 1900±866 1306±693 956±495 Change, % 2 1±9 -14±16 * -12±17 0±23 5 -3±4 -9±32 10±51 3±19 10 1±7 -26±23 **# 20±85 11±20 15 -1±5 -24±18 **## -9±41 8±23 20 -1±8 -35±12 ***## 3±26 -4±22 * P<0.05 ** P<0.01 *** P<0.001 vs. baseline
# P<0.05 ## P<0.01 ### P<0.001 vs. solvent control - PPTA-I slightly decreases the HR and BP in cat heart failure model induced by verapamil, and significantly increase the myocardial contractility and +dP/dt max, indicating that PPTA-I has the effect for improving cardiac function.
- This example relates to the experiment for cardioprotection effect of the piperphentonamine hydrochloride for injection (PPTA-I).
- In order to further evaluate the protective effect of PPTA on myocardium injured by ischemia-reperfusion, a pathological model of myocardial ischemia-reperfusion injury in cats in vivo was established by arrest the coronary artery for 30min, then reperfusion for 60min, studying the effects on blood biochemistry, myocardium ultrastructure, etc.
- The serum biochemistry results showed that PPTA-I 1.2 to 4.8 mg/kg could antagonize dose-dependently the increase of the final product of lipid-peroxidation malonaldehyde (MDA) produced by ischemia-reperfusion, decrease the activity of creatine phosphokinase (CPK) and the amount of Troponin-I (TnI). The result of myocardium ultrastructure showed that the PPTA-I significantly protect against myocardial injury. The results are shown in Table 5.
Table 5. The effects of PPTA-I on serum indices and myocardial injury in myocardial ischemia-reperfusion cats Group Drug mg/kg n Content of MDA, nmol/L CPK activity Content of cTnI Score of myocardium pathological change sham operation - 4 31±4.5 220±6 0.31±0.055 0±0 Injury control - 8 86±17 385±75 2.3±0.62 2.5±0.55 Injury + PPTA-I 1.2 6 74±9.8# 300±56# 1.5±0.42# 2.0±0.18# 2.4 6 63:10## 263±51## 1.1±0.28## 1.2±0.31## 4.8 6 55±8.7## 248±48## 0.68±0.15## 0.86±0.22## Injury+verapamil 1.3 4 65±12 ## 271±80## 1.4±0.21## 1.3±0.18 ## - It was observed on the pathological model of myocardial ischemia-reperfusion injury induced by arresting the coronary artery of cats that PPTA-I dose-dependently decreases the content of the final product of lipid-peroxidation malonaldehyde (MDA), decreases the activity of serum creatine phosphokinase (CPK) and the content of Troponin-I (TnI), and alleviates the injury of the myocardial ultrastructure. These further indicate that PPTA-I could protect heart from ischemia-reperfusion injury in vivo.
- This example relates to the clinical use of piperphentonamine hydrochloride for injection (PPTA-I) for treatment of heart failure and protection of injured myocardium. The dose for heart failure is 0.5mg/kg, administered by intravenous bolus of 10% of the dose plus intravenous infusion of remained 90% of the dose. The treatment course is 7 days. The results are shown in Table 6. The dose for myocardial protection is 1.0mg/kg, administered by intravenous infusion or adding into the cardioplegia liquid used in cardiosurgical operation for cardiac perfusion. The treatment course is 7 days as well. The results are shown in Table 7.
Table 6. The clinical efficacies of PPTA-I on acute and chronic cardiac dysfunction. Efficacy indices Group n Decrease of pulmonary capillary wedge pressure, % Increase of ejection fraction, % Decrease of Brain natriuretic peptide, % Symptom improvement, % Total effective rate, % Control 15 5.2±8.5 7.8±9.6 10±15 40 53 PPTA-I 45 35±12 56±23 41±18 88.9 84 Table 7. The clinical efficacies of PPTA-I on myocardial injury in both of cardiac internal medicine and cardiac surgery. Efficacy indices Group n Increase of ejection fraction, % Decrease of troponin, % Symptom improvement, % Total effective rate, % Valve replacement control 1 20 48±25 15±10 100 90 PPTA-I 35 65±26 48±18 100 100 Bypass surgery control 2 20 26±15 8.9±5.7 90 90 PPTA-I 35 43±17 21±9.4 100 100 ACS control 3 30 31±11 11±13 87 83 PPTA-I 30 56±24 42±15 93 97 ACS: Acute Coronary Syndrome - The above results suggest that compared with the excipient control groups, the treatment effect of PPTA-I is obvious by improving the cardiac function significantly and alleviating the myocardial injury.
Claims (6)
- A piperphentonamine hydrochloride lyophilized powder for injection, which is prepared by the following components by weight via freeze-drying:400 - 600 parts of water for injection with pH 1.5 to 5.5,1 part of piperphentonamine hydrochloride, and5 -20 parts of mannitol as excipientwhereinthe pH of water for injection is adjusted to 2.0 to 3.0 by an acidic solution which is hydrochloric acid solution, phosphate buffer or acetate buffer,throughweighing the piperphentonamine hydrochloride and the excipient, adding 500 parts of water for injection, raising the temperature up to 60°C, ultrasonic dissolving, degerming and split charging, decreasing the temperature of a sample chamber to -25°C to -35°C, then placing the split charged sample into it for pre-freezing for 3 to 7 hours, increasing the temperature to -20°C to -10°C for freeze dehydrating for 15 to 25 hours, and again increasing the temperature to 20 °C to 30°C for drying for 5 to 15 hours,orweighing the piperphentonamine hydrochloride and the excipient, adding 500 parts of water for injection, raising the temperature up to 60°C, ultrasonic dissolving, degerming and split charging, placing the split charged sample into a sample chamber, then decreasing the temperature of the sample chamber to -25°C to -35°C for pre-freezing for 2 to 4 hours, increasing the temperature to -20°C to -10°C for freeze dehydrating for 15 to 25 hours, and again increasing the temperature to 20°C to 30°C for drying for 5 - 15 hours.
- The piperphentonamine hydrochloride lyophilized powder for injection according to claim 1, characterized by 10 parts of mannitol as excipient.
- A method for preparing the piperphentonamine hydrochloride lyophilized powder for injection of claim 1, comprising the steps of:weighing the piperphentonamine hydrochloride and the excipient, adding 500 parts of water for injection, raising the temperature up to 60°C, ultrasonic dissolving, degerming and split charging,decreasing the temperature of the sample chamber to -25°C - -35°C, then placing the split charged sample into it for pre-freezing for 3-7 hours, increasing the temperature to -20°C - -10°C for freeze dehydrating for 15 - 25 hours, and again increasing the temperature to 20 °C- 30°C for drying for 5 - 15 hours;orweighing the piperphentonamine hydrochloride and the excipient, adding 500 parts of water for injection, raising the temperature up to 60°C, ultrasonic dissolving, degerming and split charging,placing the split charged sample into the sample chamber, then decreasing the temperature of the sample chamber to -25°C - -35°C for pre-freezing for 2 - 4 hours, increasing the temperature to - 20°C - -10°C for freeze dehydrating for 15 - 25 hours, and again increasing the temperature to 20°C - 30°C for drying for 5 - 15 hours;and finally capping and packing.
- The method for preparing the piperphentonamine hydrochloride lyophilized powder for injection according to claim 3, characterized in that said degerming is filtering via positive pressure, and the glass bottle is brown.
- A use of the piperphentonamine hydrochloride lyophilized powder for injection according to claim 1 for preparing a medication for treatment of heart failure.
- A use of the piperphentonamine hydrochloride lyophilized powder for injection according to claim 1 for preparing a medication for cardioprotection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2007/000337 WO2008095328A1 (en) | 2007-01-31 | 2007-01-31 | A kind of hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2151239A1 EP2151239A1 (en) | 2010-02-10 |
EP2151239A4 EP2151239A4 (en) | 2010-11-24 |
EP2151239B1 true EP2151239B1 (en) | 2012-04-25 |
Family
ID=39681231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07710861A Active EP2151239B1 (en) | 2007-01-31 | 2007-01-31 | Hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (1) | US8513301B2 (en) |
EP (1) | EP2151239B1 (en) |
AT (1) | ATE554759T1 (en) |
WO (1) | WO2008095328A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028681B (en) * | 2009-09-24 | 2012-05-30 | 广州市众为生物技术有限公司 | Application of peperphentonamine or salt thereof in preparing drug for preventing/treating encephalopathy |
US9394243B2 (en) | 2011-06-24 | 2016-07-19 | Solvay Specialty Polymers Italy S.P.A. | (per)fluoropolyether block copolymers |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5628700A (en) * | 1999-06-21 | 2001-01-09 | Edson X. Albuquerque | Thienylhydrazon with digitalis-like properties (positive inotropic effects) |
CN1166660C (en) | 2002-07-24 | 2004-09-15 | 广州市众为生物技术有限公司 | Process for preparing N-methyl piperethanamine salt |
CN1164585C (en) | 2002-07-24 | 2004-09-01 | 广州市众为生物技术有限公司 | Xanthiphenyl ketamine or its salt and its preparing process |
CN1205928C (en) | 2002-07-24 | 2005-06-15 | 广州市众为生物技术有限公司 | Application of xanthiphenylketamine or its salt in preparing medicines to treat cardiovascalar disease |
CN1190195C (en) | 2003-07-14 | 2005-02-23 | 杭州容立医药科技有限公司 | Metaduocine freeze-dried powder injection preparation and its preparation method |
-
2007
- 2007-01-31 US US12/598,356 patent/US8513301B2/en active Active
- 2007-01-31 WO PCT/CN2007/000337 patent/WO2008095328A1/en active Application Filing
- 2007-01-31 AT AT07710861T patent/ATE554759T1/en active
- 2007-01-31 EP EP07710861A patent/EP2151239B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
ATE554759T1 (en) | 2012-05-15 |
EP2151239A1 (en) | 2010-02-10 |
WO2008095328A1 (en) | 2008-08-14 |
US20100197731A1 (en) | 2010-08-05 |
EP2151239A4 (en) | 2010-11-24 |
US8513301B2 (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113166060B (en) | Treatment of sickle cell disease with pyruvate kinase-activating compounds | |
KR101502533B1 (en) | Stable pharmaceutical composition containing Taxane derivatives, and method of manufacturing the same | |
US20170319640A1 (en) | Formulations and Methods of Administration of Cephalotaxines, Including Homoharringtonine | |
EP3603660A1 (en) | New application for long-acting mutant human fibroblast growth factor | |
EP2991619B1 (en) | Stable pharmaceutical composition containing folates | |
EP2952184B1 (en) | Pharmaceutical formulation for treating pancreatic cancer | |
EP2589382A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
CN104138377A (en) | A pharmaceutical composition treating severe high-altitude diseases | |
CN109731106A (en) | A kind of preparation method for treating glioma compound | |
EP3650009A1 (en) | Preparation of pulsatilla saponin b4 for injection | |
JP2020125359A (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
US20090143300A1 (en) | Treatment of sepsis and septic shock using ghrelin and growth hormone | |
EP2151239B1 (en) | Hydrochloric piperphentonamine freeze-dried powder injection, preparation methods and uses thereof | |
JP2010535159A (en) | Use of Leonurine and compositions thereof | |
HU228861B1 (en) | The use of docetaxel for production amedicament, useful for treating hepatocellular carcinoma | |
CN101234102B (en) | Peperphentonamine hydrochloride freeze-dried injection and preparation and application thereof | |
RU2519654C2 (en) | Tetrodotoxin-based lyophilised preparation and method of its production | |
JP2018533601A (en) | L-ornithine phenyl acetate preparation | |
JP3253302B2 (en) | Parenteral solution containing 3-dialkylaminoethoxybenzoyl-benzofuran | |
CN101317846B (en) | Tetrodotoxin formulation for drug rehabilitation , pain ease | |
CN101891751B (en) | Method for preparing tetrodotoxin | |
CN104936592A (en) | Hpph lyophilized powder injection for injection and preparation method thereof | |
US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
JP3022915B2 (en) | Cancer metastasis inhibitor | |
CN102757471A (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091204 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20101026 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 317/48 20060101ALI20111007BHEP Ipc: A61K 31/36 20060101AFI20111007BHEP Ipc: A61K 9/00 20060101ALI20111007BHEP Ipc: A61K 9/19 20060101ALI20111007BHEP |
|
RTI1 | Title (correction) |
Free format text: HYDROCHLORIC PIPERPHENTONAMINE FREEZE-DRIED POWDER INJECTION, PREPARATION METHODS AND USES THEREOF |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: GUANGZHOU ZHONGWEI BIOTECHNOLOGY LTD |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 554759 Country of ref document: AT Kind code of ref document: T Effective date: 20120515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007022239 Country of ref document: DE Effective date: 20120621 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20120425 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 554759 Country of ref document: AT Kind code of ref document: T Effective date: 20120425 |
|
LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120825 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120827 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120726 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20130128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120805 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007022239 Country of ref document: DE Effective date: 20130128 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120725 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602007022239 Country of ref document: DE Owner name: WUXI JIMINKEXIN SHANHE PHARMACEUTICAL CO., LTD, CN Free format text: FORMER OWNER: GUANGZHOU ZHONGWEI BIOTECHNOLOGY LTD, GUANGZHOU, CN Effective date: 20140403 Ref country code: DE Ref legal event code: R082 Ref document number: 602007022239 Country of ref document: DE Representative=s name: BECK & ROESSIG - EUROPEAN PATENT ATTORNEYS, DE Effective date: 20140403 Ref country code: DE Ref legal event code: R081 Ref document number: 602007022239 Country of ref document: DE Owner name: WUXI JIMINKEXIN SHANHE PHARMACEUTICAL CO., LTD, CN Free format text: FORMER OWNER: GUANGZHOU ZHONGWEI BIOTECHNOLOGY LTD, GUANGZHOU, LUOGANG DISTRICT, CN Effective date: 20140403 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20140424 AND 20140430 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP Owner name: WUXI JIMINKEXIN SHANHE PHARMACEUTICAL CO., LTD, CN Effective date: 20140818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120425 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070131 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20130131 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602007022239 Country of ref document: DE Representative=s name: BECK & ROESSIG - EUROPEAN PATENT ATTORNEYS, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602007022239 Country of ref document: DE Owner name: WUXI JIYU SHANHE PHARMACEUTICAL CO., LTD., WUX, CN Free format text: FORMER OWNER: WUXI JIMINKEXIN SHANHE PHARMACEUTICAL CO., LTD., WUXI, JIANGSU, CN |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230123 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240131 Year of fee payment: 18 Ref country code: GB Payment date: 20240124 Year of fee payment: 18 |